296 related articles for article (PubMed ID: 17414516)
1. Novel targets and approaches in advanced prostate cancer.
Hadaschik BA; Sowery RD; Gleave ME
Curr Opin Urol; 2007 May; 17(3):182-7. PubMed ID: 17414516
[TBL] [Abstract][Full Text] [Related]
2. New drugs in prostate cancer.
Armstrong AJ; Carducci MA
Curr Opin Urol; 2006 May; 16(3):138-45. PubMed ID: 16679849
[TBL] [Abstract][Full Text] [Related]
3. Targeted therapeutic approaches for hormone-refractory prostate cancer.
Stavridi F; Karapanagiotou EM; Syrigos KN
Cancer Treat Rev; 2010 Apr; 36(2):122-30. PubMed ID: 20106600
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic options for hormone-refractory prostate cancer in 2007.
Hadaschik BA; Gleave ME
Urol Oncol; 2007; 25(5):413-9. PubMed ID: 17826663
[TBL] [Abstract][Full Text] [Related]
5. Angiogenesis as a strategic target for prostate cancer therapy.
Li Y; Cozzi PJ
Med Res Rev; 2010 Jan; 30(1):23-66. PubMed ID: 19536866
[TBL] [Abstract][Full Text] [Related]
6. Targeted therapy for advanced prostate cancer: Looking through new lenses.
Vogiatzi P; Cassone M; Claudio L; Claudio PP
Drug News Perspect; 2009 Dec; 22(10):593-601. PubMed ID: 20140279
[TBL] [Abstract][Full Text] [Related]
7. Management of the spectrum of hormone refractory prostate cancer.
Clarke NW
Eur Urol; 2006 Sep; 50(3):428-38; discussion 438-9. PubMed ID: 16797118
[TBL] [Abstract][Full Text] [Related]
8. Second-line chemotherapy for advanced hormone-refractory prostate cancer.
Garmey EG; Sartor O; Halabi S; Vogelzang NJ
Clin Adv Hematol Oncol; 2008 Feb; 6(2):118-22, 127-32. PubMed ID: 18347563
[TBL] [Abstract][Full Text] [Related]
9. Novel therapies for advanced prostate cancer.
Konety BR; Getzenberg RH
Semin Urol Oncol; 1997 Feb; 15(1):33-42. PubMed ID: 9050138
[TBL] [Abstract][Full Text] [Related]
10. Beyond simple castration: targeting the molecular basis of treatment resistance in advanced prostate cancer.
Gleave M; Miyake H; Chi K
Cancer Chemother Pharmacol; 2005 Nov; 56 Suppl 1():47-57. PubMed ID: 16273354
[TBL] [Abstract][Full Text] [Related]
11. Actual chemotherapeutical possibilities in hormone-refractory prostate cancer (HRPC) patients.
Prezioso D; Galasso R; Di Martino M; Iapicca G; Annunziata E; Iacono F
Anticancer Res; 2007; 27(2):1095-104. PubMed ID: 17465249
[TBL] [Abstract][Full Text] [Related]
12. Update on castrate-resistant prostate cancer: 2010.
Lassi K; Dawson NA
Curr Opin Oncol; 2010 May; 22(3):263-7. PubMed ID: 20177381
[TBL] [Abstract][Full Text] [Related]
13. Novel cytotoxic and biological agents for prostate cancer: where will the money be in 2005?
Strother JM; Beer TM; Dreicer R
Eur J Cancer; 2005 Apr; 41(6):954-64. PubMed ID: 15808961
[TBL] [Abstract][Full Text] [Related]
14. Novel therapeutic strategies in prostate cancer: establishing a stratification system for patient selection in targeted trials.
Priolo C; Oh WK; Loda M
IDrugs; 2009 Mar; 12(3):165-8. PubMed ID: 19333896
[TBL] [Abstract][Full Text] [Related]
15. New molecular targets in advanced prostate cancer.
Dawson NA
Expert Rev Anticancer Ther; 2006 Jul; 6(7):993-1002. PubMed ID: 16831072
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy for prostate cancer - recent progress in clinical trials.
Kipp RT; McNeel DG
Clin Adv Hematol Oncol; 2007 Jun; 5(6):465-74, 477-9. PubMed ID: 17679921
[TBL] [Abstract][Full Text] [Related]
17. Role of targeted therapy in the treatment of advanced prostate cancer.
Fizazi K; Sternberg CN; Fitzpatrick JM; Watson RW; Tabesh M
BJU Int; 2010 Mar; 105(6):748-67. PubMed ID: 20353536
[TBL] [Abstract][Full Text] [Related]
18. Molecular genetics and mechanisms of apoptosis in carcinomas of the lung and pleura: therapeutic targets.
Motadi LR; Misso NL; Dlamini Z; Bhoola KD
Int Immunopharmacol; 2007 Dec; 7(14):1934-47. PubMed ID: 18039530
[TBL] [Abstract][Full Text] [Related]
19. Future innovations in treating advanced prostate cancer.
Desai P; Jiménez JA; Kao C; Gardner TA
Urol Clin North Am; 2006 May; 33(2):247-72, viii. PubMed ID: 16631463
[TBL] [Abstract][Full Text] [Related]
20. Angiogenesis inhibition plus chemotherapy for metastatic hormone refractory prostate cancer: history and rationale.
Ryan CJ; Lin AM; Small EJ
Urol Oncol; 2006; 24(3):250-3. PubMed ID: 16678059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
